HPV-induced cancers are also managed with HDAC and DNMT inhibitors, YAP/TEAD pathway inhibitors, and immunotherapies like pembrolizumab, offering comprehensive treatment options (Bertagnin et al., 2023; Martinez et al., 2022; Martinez et al., 2022; Yao et al., 2024; Zeidan et al., 2022; Jabbour et al., 2017; Pan et al., 2023; Yang et al., 2021). Here, YAP1 is linked to cancer.